Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia Jan 9, 2023
Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis Dec 6, 2022
Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances Nov 7, 2022
Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update Nov 4, 2022
Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA) Nov 2, 2022
Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting Oct 24, 2022
Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Disease Oct 6, 2022
Ocuphire Expands Medical Advisory Board with Seven New KOLs and Strengthens Leadership Team Sep 29, 2022
